ViiV Healthcare presents data from Phase III study of dolutegravir vs raltegravir in treatment-experienced adults with HIV-1
6 March 2013 | By GlaxoSmithKline
24-week data from Phase III SAILING study...
List view / Grid view
6 March 2013 | By GlaxoSmithKline
24-week data from Phase III SAILING study...
28 February 2013 | By
Agreement brings the number of voluntary...
15 February 2013 | By GlaxoSmithKline
The FDA has granted a priority review designation to dolutegravir...
17 December 2012 | By GlaxoSmithKline
“These regulatory submissions are an important step for ViiV Healthcare..."
13 November 2012 | By GlaxoSmithKline
24-week data from VIKING-3 Phase III study...
29 October 2012 | By GlaxoSmithKline
ViiV Healthcare Ltd and Shionogi & Co., Ltd., have entered into an agreement...
2 April 2012 | By GlaxoSmithKline
SPRING-2 study meets primary endpoint of non-inferiority of dolutegravir...
25 February 2011 | By GlaxoSmithKline
GSK, ViiV Healthcare, & Pfizer announced the appointment of David Redfern as the new Chairman of the Board for ViiV Healthcare...